A Single Center, Randomized, Double-blind, and Intergroup Control Clinical Study to Evaluation on Lot-to-lot Consistency and Immune Persistence of Three Commercial Batches of 23 Valent Pneumococcal Polysaccharide Vaccine
Latest Information Update: 08 Apr 2024
At a glance
- Drugs Pneumococcal polysaccharide 23 valent vaccine Beijing Zhifei Lvzhu Biopharmaceutical (Primary)
- Indications Pneumococcal infections
- Focus Pharmacodynamics; Registrational
- Sponsors Beijing Zhifei Lvzhu Biopharmaceutical
Most Recent Events
- 20 Mar 2024 New trial record